BMS and ipilimumab: Co-operation with academia and other companies yields success

A new metastatic melanoma product, ipilimumab (sold as Yervoy), from Bristol-Myers Squibb (BMS), has the potential to be a blockbuster. Malignant melanoma is increasing in frequency and this is the first new drug approved for the condition since 1998. Unlike previous treatments, it has been shown to increase life expectancy in patients by several months on average, and 28% are alive after two years, compared with just 14% using the previous treatment. Rather than the story of a single innovation, ipilimumab’s development shows how co-operation can yield a series of innovations that are sometimes needed to create a new drug.

Enjoy in-depth insights and expert analysis - subscribe to our Perspectives newsletter, delivered every week